Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Events
  4.  » AAPS 2022 PharmSci 360

AAPS 2022 PharmSci 360

Schedule a Meeting with Catalent at AAPS 2022 PharmSci 360

Date: October 16-19, 2022
Location: Boston Convention & Exhibition Center, Boston, MA




Karu S's headshot

Karunakar Sukuru, R.Ph., Ph.D.

Vice President-Rx Product Development, Softgel & Oral Technologies, Catalent



Session Title: A Patient Centric Solution for Development of Oral Dosage Forms
Date: Monday, October 17, 2022
Time: 3:30 PM – 4:30 PM ET
Location: 360 Stage, Exhibit Halls A&B
Track: Formulation and Delivery
Abstract: Recent progress in formulation and manufacturing techniques allows for the development of innovative softgels with several benefits. By varying the shell and the fill formulation, the release properties of softgel content can be modulated. With various presentation formats such as tablet-in-softgel or softgel in stick pack, the needs of different patients and consumers in the pharma and supplement markets can be met. The utility of stick pack for delivering large doses will also be discussed.

Learning Objectives:

    • Understand the evolution of softgels as a patient-centric dosage form
    • Describe the in vitro dissolution and stability profile of delayed-release softgels
    • Understand the utility of stick-packs for the delivery of a variety of multiparticulates



Nathan Bennette's headshot

Nathan Bennette
Director, Scientific Advisory, Catalent




Session Title: Exploring Protein Degrader Drug Delivery Challenges
Date: Tuesday, October 18, 2022
Time: 10:30 AM – 11:30 AM ET
Location: 360 Stage, Exhibit Halls A&B
Track: Preclinical Development
Abstract: Targeted protein degraders, and more specifically PROTACs, have the potential to revolutionize the way we design new therapies. Key challenges in the development of PROTACs into orally bioavailable therapies are a result of their unconventional structures and distinctive physicochemical properties. These molecules do not conform to Lipinski’s Rule of 5 for small molecules and often require more complex drug delivery strategies. This presentation will discuss the significant challenges, opportunities, and potential solutions to oral delivery of PROTACs.

Learning Objectives:

    • Understand why PROTACs cannot be evaluated through a conventional small molecule lens
    • Explore the key physicochemical properties that determine whether a PROTAC is likely to be orally bioavailable
    • Discuss rate limiting steps to oral absorption and how enabling technologies may enhance absorption of this class of molecule